DHDH Antibody

What is DHDH and what functional significance does it have in human tissues?

DHDH, also known as trans-1,2-dihydrobenzene-1,2-diol dehydrogenase, is a 334 amino acid protein with a molecular weight of approximately 36.4 kDa. It belongs to the Gfo/Idh/MocA protein family and has several functional roles including 3-deoxyglucosone reductase and D-xylose-NADP dehydrogenase activity . The protein is most notably expressed in the duodenum and small intestine, suggesting important digestive or metabolic functions . Recent research has implicated DHDH in D-xylose metabolism related to immune evasion in triple-negative breast cancer, highlighting its potential significance in cancer biology .

What are the primary applications for DHDH antibodies in research settings?

DHDH antibodies are utilized across multiple experimental techniques, with the most common applications being:

• Western Blot (WB): Used for protein expression quantification and molecular weight confirmation

• Immunohistochemistry (IHC): For tissue localization and expression pattern analysis

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection in solutions

• Immunofluorescence (IF): For subcellular localization studies

Some DHDH antibodies are also validated for specialized applications like Immunocytochemistry (ICC) and Immunoprecipitation (IP), depending on the specific antibody clone and manufacturer .

What is the expected molecular weight when detecting DHDH in Western blot analysis?

When performing Western blot analysis for DHDH, researchers should expect to observe a band at approximately 36-39 kDa. Specifically, while the calculated molecular weight based on amino acid sequence is 36.4 kDa, the observed molecular weight in experimental settings is typically around 39 kDa . This slight discrepancy between calculated and observed weights may be attributed to post-translational modifications or the buffer conditions used during electrophoresis. When troubleshooting or validating DHDH antibodies, this molecular weight range should be used as a reference point.

What are the recommended dilution ranges for DHDH antibodies across different applications?

Based on validated protocols, the following dilution ranges are recommended for optimal results with DHDH antibodies:

It is strongly recommended to perform dilution series optimization with each new lot of antibody and for each specific sample type to achieve optimal signal-to-noise ratio .

What antigen retrieval methods are most effective for DHDH immunohistochemistry?

For optimal DHDH detection in immunohistochemistry applications, two antigen retrieval approaches have demonstrated effectiveness:

• TE buffer pH 9.0 (recommended primary method)

• Citrate buffer pH 6.0 (alternative method)

The choice between these methods may depend on tissue type, fixation protocol, and specific antibody being used. Researchers should perform comparative studies with both retrieval methods on their specific samples to determine optimal conditions. Extended retrieval times (15-20 minutes) at lower temperatures may be preferable to short high-temperature retrieval to preserve tissue morphology while maintaining adequate epitope exposure.

How should researchers validate the specificity of DHDH antibodies?

Comprehensive validation of DHDH antibodies should include:

• Positive and negative control tissues: Use tissues with known DHDH expression (duodenum, small intestine) as positive controls, and tissues with minimal expression as negative controls.

• Knockdown/knockout validation: Compare staining between wild-type samples and those with DHDH gene silencing or knockout.

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should eliminate specific staining.

• Cross-reactivity assessment: Test reactivity across multiple species if working with non-human models. Available DHDH antibodies have demonstrated reactivity with human, mouse, and rat specimens .

• Multi-antibody concordance: Compare staining patterns using different antibody clones targeting distinct DHDH epitopes.

This systematic approach helps ensure that observed signals genuinely represent DHDH rather than non-specific binding.

How has DHDH been implicated in cancer research, and what antibody-based methods are employed?

Recent research has revealed DHDH's role in D-xylose metabolism related to immune evasion mechanisms in triple-negative breast cancer . Researchers investigating DHDH in cancer contexts typically employ a multi-modal approach:

• Expression profiling: IHC analysis of DHDH across tumor and matched normal tissues to establish expression patterns.

• Functional studies: Combining DHDH antibodies with metabolic pathway analysis to understand its role in D-xylose metabolism.

• Co-localization experiments: Dual immunofluorescence staining with DHDH antibodies and markers of immune cells to investigate immune evasion mechanisms.

• Prognostic correlation: Correlating DHDH expression levels (quantified via IHC or Western blot) with clinical outcomes and treatment responses.

When designing such studies, researchers should select antibodies validated specifically for cancer tissue types and consider the potential impact of tumor microenvironment on antibody performance.

What approaches can be used to study DHDH's enzymatic activity in conjunction with antibody-based detection?

To comprehensively understand DHDH function, researchers often combine antibody-based detection with enzymatic activity assays:

• Activity-based protein profiling: Using activity-based probes in conjunction with DHDH antibodies to correlate protein presence with enzymatic function.

• Immunoprecipitation followed by activity assay: Using DHDH antibodies for immunoprecipitation followed by measurement of D-xylose dehydrogenase activity in the precipitated fraction.

• In situ activity visualization: Coupling immunofluorescence with metabolic labeling to visualize both DHDH localization and activity in intact cells.

• Structure-function correlation: Utilizing epitope-specific antibodies targeting different DHDH domains to understand how structural elements contribute to enzymatic function.

These approaches provide insights beyond simple expression levels, allowing researchers to connect DHDH's presence with its functional significance in different physiological and pathological contexts.

What factors might contribute to inconsistent DHDH antibody staining in immunohistochemistry?

Several factors can affect the consistency and reproducibility of DHDH immunostaining:

• Fixation variables: Overfixation can mask epitopes, while underfixation may lead to tissue deterioration. Standardize fixation time (typically 24-48 hours in 10% neutral buffered formalin).

• Antigen retrieval optimization: Insufficient retrieval leads to weak staining. Compare TE buffer pH 9.0 and citrate buffer pH 6.0 methods to determine optimal conditions for your specific antibody and tissue type .

• Antibody concentration: Too high concentrations increase background, while too low concentrations reduce specific signal. Perform titration experiments to identify optimal dilution ranges .

• Endogenous peroxidase activity: Inadequate blocking of endogenous peroxidase in tissues can create false-positive signals. Ensure complete blocking (typically 3% H₂O₂ for 10 minutes).

• Tissue-specific variations: DHDH expression levels naturally vary across tissues. Use appropriate positive controls (duodenum, small intestine) to establish expected staining patterns .

Maintaining detailed protocol records and standardizing each step of the immunostaining process is essential for achieving consistent results.

How should researchers interpret multiple bands in DHDH Western blot analysis?

When multiple bands appear in Western blot analysis of DHDH, consider these interpretations and verification approaches:

• Isoform expression: DHDH may exist in multiple isoforms. Verify by comparing observed bands with predicted molecular weights of known isoforms.

• Post-translational modifications: Phosphorylation, glycosylation, or other modifications can create bands with higher apparent molecular weight than the expected 36-39 kDa. Confirm using phosphatase or glycosidase treatments prior to Western blot.

• Degradation products: Lower molecular weight bands may represent proteolytic fragments. Improve sample handling and add protease inhibitors to reduce degradation.

• Cross-reactivity: Some bands may represent non-specific binding to related proteins. Validate using knockout/knockdown controls or peptide competition assays.

• Antibody quality issues: Multiple bands may indicate antibody degradation or contamination. Test a different lot or alternative antibody clone.

The expected molecular weight for human DHDH is approximately 39 kDa in experimental Western blot conditions . Any additional bands should be systematically investigated using the approaches outlined above.

How can DHDH antibodies be utilized in studying metabolic pathway alterations in disease models?

DHDH's role in metabolic processes, particularly D-xylose metabolism, makes it an important target in disease research. Advanced approaches include:

• Metabolic flux analysis: Combining DHDH immunoprecipitation with mass spectrometry to track substrates and products in metabolic pathways.

• Single-cell analysis: Using highly specific DHDH antibodies for single-cell immunostaining to detect cell-to-cell variations in metabolic pathway components.

• In vivo imaging: Developing fluorescently labeled DHDH antibodies or fragments for real-time tracking of DHDH expression in animal disease models.

• Multi-omics integration: Correlating DHDH protein levels (detected via antibodies) with transcriptomic and metabolomic data to build comprehensive pathway models.

Researchers have already begun using these approaches to investigate DHDH's role in triple-negative breast cancer, revealing its potential involvement in immune evasion mechanisms .

What are the considerations for developing improved DHDH antibodies using new antibody engineering technologies?

Recent advances in antibody engineering offer opportunities to develop next-generation DHDH antibodies with enhanced properties:

• Structure-based engineering: Using computational approaches like those described for antibody design to develop DHDH antibodies with improved specificity and reduced immunogenicity .

• CDR walking strategies: Optimizing binding sites through sequential mutation of Complementarity-Determining Regions (CDRs) to enhance affinity and specificity for DHDH epitopes .

• Reducing pre-existing reactivity: Applying techniques to minimize unwanted cross-reactivity, such as modifications to the C-terminal region of antibody fragments that can trigger pre-existing anti-drug antibodies (ADAs) .

• Application-specific optimization: Developing antibodies specifically optimized for challenging applications like super-resolution microscopy or multiplexed imaging of DHDH in complex tissue environments.

Implementation of these advanced approaches requires sophisticated computational tools for design and rigorous validation using multiple orthogonal methods to confirm performance characteristics.

How do monoclonal and polyclonal DHDH antibodies compare in research applications?

The choice between polyclonal and monoclonal antibodies should be guided by the specific research question, required sensitivity, and importance of reproducibility for the particular application.

What methodological approaches are most effective for validating novel DHDH antibodies?

Comprehensive validation of new DHDH antibodies should follow a systematic approach:

• Initial characterization:

  • ELISA against recombinant DHDH to confirm binding

  • Western blot validation using tissues with known DHDH expression

  • Determination of optimal working dilutions for various applications

• Specificity confirmation:

  • Testing against DHDH-null samples (knockout or knockdown)

  • Peptide competition assays

  • Cross-reactivity assessment against related proteins

• Application-specific validation:

  • For IHC: Optimize antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • For WB: Confirm expected molecular weight (approximately 39 kDa)

  • For IF: Verify subcellular localization patterns

• Comparative assessment:

  • Side-by-side comparison with established antibodies

  • Multi-antibody concordance testing using antibodies against different DHDH epitopes

This comprehensive approach ensures that novel DHDH antibodies meet the rigorous standards required for reliable research applications.

How might DHDH antibodies contribute to emerging areas of metabolic and cancer research?

DHDH antibodies are poised to play crucial roles in several emerging research areas:

• Cancer metabolism: Given DHDH's involvement in D-xylose metabolism and immune evasion in triple-negative breast cancer , antibodies targeting DHDH will be valuable tools for investigating metabolic reprogramming in cancer cells.

• Biomarker development: DHDH expression patterns detected by specific antibodies may serve as potential diagnostic or prognostic biomarkers in certain cancer types.

• Therapeutic target validation: As researchers explore DHDH as a potential therapeutic target, antibodies will be essential for target validation studies and therapeutic antibody development.

• Spatial metabolomics: Combining DHDH antibodies with advanced imaging techniques will enable spatial mapping of metabolic pathways in complex tissues.

• Single-cell analysis: Integration of DHDH antibodies into single-cell proteomic workflows will reveal cell-to-cell heterogeneity in metabolic enzyme expression.

These applications will require continued refinement of antibody specificity and sensitivity, along with development of new formats optimized for emerging technological platforms.

What considerations are important when selecting DHDH antibodies for multi-omics research approaches?

Researchers integrating antibody-based DHDH detection into multi-omics workflows should consider:

• Compatibility with tissue preservation methods: Ensure antibody performance is maintained with preservation protocols compatible with other omics techniques (e.g., spatial transcriptomics).

• Epitope accessibility in multiplex settings: Select antibodies targeting epitopes that remain accessible when using multiplexed detection systems.

• Cross-platform validation: Validate that protein levels detected by antibodies correlate appropriately with mRNA levels or metabolic measurements.

• Clone selection for reproducibility: Prefer well-characterized monoclonal antibodies with demonstrated lot-to-lot consistency for longitudinal studies.

• Data integration considerations: Choose antibodies and detection methods that generate quantitative data suitable for integration with other omics datasets.